Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Enhanced T cell effector activity by targeting the Mediator kinase module.
Freitas KA, Belk JA, Sotillo E, Quinn PJ, Ramello MC, Malipatlolla M, Daniel B, Sandor K, Klysz D, Bjelajac J, Xu P, Burdsall KA, Tieu V, Duong VT, Donovan MG, Weber EW, Chang HY, Majzner RG, Espinosa JM, Satpathy AT, Mackall CL. Freitas KA, et al. Among authors: mackall cl. Science. 2022 Nov 11;378(6620):eabn5647. doi: 10.1126/science.abn5647. Epub 2022 Nov 11. Science. 2022. PMID: 36356142 Free PMC article.
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, Shalabi H, Fountaine TJ, Shern JF, Majzner RG, Stroncek DF, Sabatino M, Feng Y, Dimitrov DS, Zhang L, Nguyen S, Qin H, Dropulic B, Lee DW, Mackall CL. Fry TJ, et al. Among authors: mackall cl. Nat Med. 2018 Jan;24(1):20-28. doi: 10.1038/nm.4441. Epub 2017 Nov 20. Nat Med. 2018. PMID: 29155426 Free PMC article. Clinical Trial.
Engineering a designer immunotherapy.
Mackall CL. Mackall CL. Science. 2018 Mar 2;359(6379):990-991. doi: 10.1126/science.aas9434. Science. 2018. PMID: 29496866 No abstract available.
Neurotoxicity Associated with a High-Affinity GD2 CAR-Letter.
Majzner RG, Weber EW, Lynn RC, Xu P, Mackall CL. Majzner RG, et al. Among authors: mackall cl. Cancer Immunol Res. 2018 Apr;6(4):494-495. doi: 10.1158/2326-6066.CIR-18-0089. Cancer Immunol Res. 2018. PMID: 29610423 No abstract available.
Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas.
Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, Haile S, Labanieh L, Hulleman E, Woo PJ, Rietberg SP, Vogel H, Monje M, Mackall CL. Mount CW, et al. Among authors: mackall cl. Nat Med. 2018 May;24(5):572-579. doi: 10.1038/s41591-018-0006-x. Epub 2018 Apr 16. Nat Med. 2018. PMID: 29662203 Free PMC article.
Tumor Antigen Escape from CAR T-cell Therapy.
Majzner RG, Mackall CL. Majzner RG, et al. Among authors: mackall cl. Cancer Discov. 2018 Oct;8(10):1219-1226. doi: 10.1158/2159-8290.CD-18-0442. Epub 2018 Aug 22. Cancer Discov. 2018. PMID: 30135176 Review.
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C, Sotillo E, Labanieh L, Lee DW, Orentas RJ, Dimitrov DS, Zhu Z, Croix BS, Delaidelli A, Sekunova A, Bonvini E, Mitra SS, Quezado MM, Majeti R, Monje M, Sorensen PHB, Maris JM, Mackall CL. Majzner RG, et al. Among authors: mackall cl. Clin Cancer Res. 2019 Apr 15;25(8):2560-2574. doi: 10.1158/1078-0432.CCR-18-0432. Epub 2019 Jan 17. Clin Cancer Res. 2019. PMID: 30655315 Free PMC article.
256 results